Patent ID: 8889138

Claim:
An isolated antibody, or an antigen binding fragment of the antibody, that binds amyloid β-derived diffusible ligands comprising: (a) a light chain variable region comprising, (i) a CDR1 having the sequence Arg-Ser-Ser-Gln-Ser-Xaa 1 -Xaa 2 -His-Ser-Asn-Gly-Asn-Thr-Tyr-Leu-Xaa 3 (SEQ ID NO:52), wherein Xaa 1 and Xaa 2 are independently Ala, Val, Leu, Ile or P, and Xaa 3 is Asp, Glu, Arg, His or Lys, (ii) a CDR2 having the sequence Lys-Xaa 1 -Ser-Asn-Arg-Phe-Xaa 2 (SEQ ID NO:57), wherein Xaa 1 is Ala, Val, Leu, Ile, or Pro, and Xaa 2 is Ser or Phe, and (iii) a CDR3 having the sequence Xaa 1 -Gln-Xaa 2 -Xaa 3 -Xaa 4 -Val-Pro-Xaa 5 -Thr (SEQ ID NO:65), wherein Xaa 1 is Ser or Phe, Xaa 2 is Gly, Ser or Thr, Xaa 3 is Ser or Thr, Xaa 4 is His, Tyr or Leu, and Xaa 5 is Ala, Val, Leu, Ile, or Pro; or Xaa 1 -Gln-Xaa 2 -Thr-Arg-Val-Pro-Leu-Thr, wherein Xaa 1 is Phe or Leu, and Xaa 2 is Ala or Thr, and (b) a heavy chain variable region comprising, (i) a CDR1 having the sequence Thr-Ser-Gly-Met-Gly-Val-Xaa (SEQ ID NO:27), wherein Xaa is Ser, Gly or Ala, (ii) a CDR2 having the sequence His-Ile-Xaa 1 -Trp-Asp-Asp-Asp-Lys-Xaa 2 -Tyr-Asn-Pro-Ser-Leu-Lys-Ser (SEQ ID NO:32), wherein Xaa 1 is Phe, Tyr or Trp and Xaa 2 is Ser, Arg, or Tyr, and (iii) a CDR3 of SEQ ID NO:43.